

# Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/GF66C19399DEN.html>

Date: December 2019

Pages: 561

Price: US\$ 2,000.00 (Single User License)

ID: GF66C19399DEN

## Abstracts

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2019

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2019, provides an overview of the Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline landscape.

Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 18, 18, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) (Oncology).

The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics and enlists all their major and minor

projects.

The pipeline guide evaluates Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Gastrointestinal Stromal Tumor (GIST) - Overview

Gastrointestinal Stromal Tumor (GIST) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development

AB Science SA

ABL Bio Inc

Advanced Accelerator Applications SA

Advenchen Laboratories LLC

Arog Pharmaceuticals Inc

ArQule Inc

Ascentage Pharma Group International

Bayer AG

Blueprint Medicines Corp

Calithera Biosciences Inc

Chipscreen Biosciences Ltd

CStone Pharmaceuticals Co Ltd

Daiichi Sankyo Co Ltd

Deciphera Pharmaceuticals Inc

Eli Lilly and Co

Esperas Pharma Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Hanmi Pharmaceuticals Co Ltd

Hefei Cosource Pharmaceutical Inc

Horizon Therapeutics PLC

Immunicum AB  
Ipsen SA  
Jiangsu Hengrui Medicine Co Ltd  
Karyopharm Therapeutics Inc  
Marino Biotechnology Co Ltd  
Merck & Co Inc  
Merck KGaA  
NantCell Inc  
Natco Pharma Ltd  
Ningbo Tai Kang Medical Technology Co Ltd  
NMS Group SpA  
Novartis AG  
Omeros Corp  
Pfizer Inc  
Pharma Mar SA  
Plexxikon Inc  
Rhizen Pharmaceuticals SA  
Sartar Therapeutics Ltd  
Shanghai Haihe Biopharma Co Ltd  
Shijiazhuang Yiling Pharmaceutical Co Ltd  
SignalRx Pharmaceuticals Inc  
Soricimed Biopharma Inc  
Taiho Pharmaceutical Co Ltd  
Takeda Pharmaceutical Co Ltd  
Xencor Inc  
Gastrointestinal Stromal Tumor (GIST) - Drug Profiles  
ABL-001 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
aldoxorubicin - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects  
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products  
Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones  
Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H2 2019

Gastrointestinal Stromal Tumor (GIST) - Pipeline by ABL Bio Inc, H2 2019

Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H2 2019

Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H2 2019 (Contd..1), H2 2019

Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019



## I would like to order

Product name: Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/GF66C19399DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF66C19399DEN.html>